CytomX Therapeutics Competitors, Revenue, Alternatives and Pricing

Claim your profile


Total Funding:$184.4M
Lead Investor(s):Fidelity Management & Research Company

Industry Ranking

Estimated Revenue & Financials

  • CytomX Therapeutics's estimated annual revenue is currently $59.5M per year.
  • CytomX Therapeutics received $70.0M in venture funding in June 2015.
  • CytomX Therapeutics's estimated revenue per employee is $334,281
  • CytomX Therapeutics's total funding is $184.4M.

Employee Data

  • CytomX Therapeutics has 178 Employees.
  • CytomX Therapeutics grew their employee count by 24% last year.
  • CytomX Therapeutics currently has 32 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
Missing a competitor? Contribute!?

CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody therapeutics. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company's pipeline includes proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company, MD Anderson Cancer Center and ImmunoGen, Inc. For more information, visit or follow us on Twitter.

keywords:Biotechnology,Healthcare,Human Resources Hr,Pharmaceuticals


Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







CytomX Therapeutics News

09/03/2019 - CytomX Therapeutics to Present at Upcoming Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (CTMX), a clinical-stage oncology-focused ...

09/08/2019 - Why CytomX Therapeutics, Inc. (CTMX) Stock is Down Almost -4.05% Today

What just happened? CytomX Therapeutics, Inc. (NASDAQ:CTMX) stock value has plummeted by nearly -4.05% or (-0.36 points) to $8.52 from ...

09/03/2019 - CytomX Therapeutics Inc (NASDAQ:CTMX) Receives $20.91 Consensus PT from Analysts

CytomX Therapeutics Inc (NASDAQ:CTMX) has received a consensus recommendation of “Buy” from the fourteen brokerages that are covering ...

CytomX Therapeutics Funding

DateAmountRoundLead InvestorsReference
2012-08-01$41.0MBCanaan PartnersArticle
2015-01-07$20.0MCPfizer Venture InvestmentsArticle
2015-06-17$70.0MDFidelity Management & Research CompanyArticle

CytomX Therapeutics Executive Hires

2010-11-22Ajay ChadhaChief Scientific OfficerArticle
2011-01-06Sean McCarthyChief Business OfficerArticle
2011-10-07Henry LowmanChief Scientific OfficerArticle
2012-03-07Hoyoung HuhChairmanArticle
2013-07-17Krishna PoluChief Medical OfficerArticle
2015-01-06W. Michael KavanaughChief Scientific Officer/Head Research/Early DevelopmentArticle
2015-05-28Bob GoeltzChief Financial OfficerArticle
2015-08-04Debanjan Raysenior vice president of corporate development and strategyArticle
2017-05-17Debanjan RayCFO/Head Corporate DevelopmentArticle